NCT02063386View on ClinicalTrials.gov

AZD1722 Open Label, Absorption Distribution Metabolism and Excretion Study

PHASE1CompletedINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

April 30, 2014

Primary Completion Date

May 31, 2014

Study Completion Date

May 31, 2014

Conditions
Healthy Volunteers
Interventions
DRUG

AZD1722

Single oral dose 15 mg of \[14C\]AZD1722

Trial Locations (1)

Unknown

Research Site, London

Sponsors

Lead Sponsor

Ardelyx
All Listed Sponsors
lead

Ardelyx

INDUSTRY

NCT02063386 - AZD1722 Open Label, Absorption Distribution Metabolism and Excretion Study | Biotech Hunter | Biotech Hunter